We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
Read MoreHide Full Article
NextGen Healthcare, Inc. delivered adjusted earnings per share (“EPS”) of 24 cents in the third quarter of fiscal 2022, down 7.7% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 14.3%.
GAAP EPS in the quarter was 8 cents, reflecting a stupendous surge of 700% from the year-earlier figure.
Revenue Details
NextGen registered revenues of $149.7 million in the fiscal third quarter, up 5.6% year over year. The figure surpassed the Zacks Consensus Estimate by 2.5%.
Segment Details
NextGen generates revenues from two sources — Recurring revenues, and Software, hardware and other non-recurring revenues.
Total Recurring revenues (89.8% of total revenues) were $134.5 million, up 4.9% from the year-ago quarter.
Total Software, hardware and other non-recurring revenues (10.2% of total revenues) amounted to $15.2 million, up 12.7% on a year-over-year basis.
NextGen Healthcare, Inc. Price, Consensus and EPS Surprise
In the quarter under review, NextGen’s adjusted gross profit rose 3.7% to $83.7 million. However, adjusted gross margin contracted 105 basis points (bps) to 55.9%.
Selling, general and administrative expenses fell 3.5% to $47.2 million. Research and development expenses went up 6.6% year over year to $19.4 million. Adjusted operating expenses of $66.6 million dipped 0.8% year over year.
Adjusted operating profit totaled $17.1 million, reflecting a 25.8% uptick from the prior-year quarter. Adjusted operating margin in the fiscal third quarter expanded 183 bps to 11.4%.
Financial Position
NextGen exited the third quarter of fiscal 2022 with cash and cash equivalents of $49.4 million compared with $75.3 million at the end of fiscal second quarter.
Cumulative net cash flow from operating activities at the end of the third quarter of fiscal 2022 was $36.6 million compared with $75.9 million a year ago.
In October 2021, NextGen’s management approved a $60-million share repurchase program. In the reported quarter, the company purchased approximately 2.2 million shares, worth $35.9 million, in the open market.
Fiscal 2022 Guidance
NextGen has raised its financial outlook for fiscal 2022.
The company now projects revenues in the range of $591-$595 million (up from the previously guided range of $584-$590 million). The Zacks Consensus Estimate for the same is pegged at $588.1 million.
Adjusted EPS is now projected in the band of 96 cents-$1.00 (up from the prior guidance of 90-96 cents). The Zacks Consensus Estimate for the same stands at 95 cents.
Our Take
NextGen exited the third quarter of fiscal 2022 with better-than-expected results. Solid uptick in top line, along with strength in both revenue sources of the company, is encouraging. Robust increase in Subscription services revenues in the quarter on the back of solid demand for NGE software-as-a-service and Virtual Visit solutions are encouraging. Expansion in adjusted operating margin bodes well. The provision of an upbeat financial outlook for the year also raises optimism.
On the flip side, year-over-year decline in adjusted EPS is disappointing. Contraction of adjusted gross margin is worrying. NextGen faces intense competition in the MedTech space, raising our apprehensions.
Zacks Rank and Key Picks
NextGen Healthcare currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks that are supposed to report earnings soon are Cerner Corporation , Catalent, Inc. (CTLT - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
The Zacks Consensus Estimate for Cerner’s fourth-quarter 2021 adjusted EPS is currently pegged at 88 cents. The consensus estimate for fourth-quarter 2021 revenues is pegged at $1.49 billion. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cerner has an estimated long-term growth rate of 12.8%. CERN’s earnings yield of 4% compare favorably with the industry’s negative yield.
Catalent currently has a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2022 adjusted EPS is currently pegged at 84 cents. The consensus estimate for fiscal second-quarter revenues is pinned at $1.16 billion.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings yield of 3.8% compare favorably with the industry’s negative yield.
AMN Healthcare currently flaunts a Zacks Rank #1. The Zacks Consensus Estimate for its fourth-quarter 2021 adjusted EPS is currently pegged at $2.58. The consensus estimate for its revenues stands at $1.28 billion.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings yield of 6.9% compare favorably with the industry’s 1.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
NextGen Healthcare, Inc. delivered adjusted earnings per share (“EPS”) of 24 cents in the third quarter of fiscal 2022, down 7.7% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 14.3%.
GAAP EPS in the quarter was 8 cents, reflecting a stupendous surge of 700% from the year-earlier figure.
Revenue Details
NextGen registered revenues of $149.7 million in the fiscal third quarter, up 5.6% year over year. The figure surpassed the Zacks Consensus Estimate by 2.5%.
Segment Details
NextGen generates revenues from two sources — Recurring revenues, and Software, hardware and other non-recurring revenues.
Total Recurring revenues (89.8% of total revenues) were $134.5 million, up 4.9% from the year-ago quarter.
Total Software, hardware and other non-recurring revenues (10.2% of total revenues) amounted to $15.2 million, up 12.7% on a year-over-year basis.
NextGen Healthcare, Inc. Price, Consensus and EPS Surprise
NextGen Healthcare, Inc. price-consensus-eps-surprise-chart | NextGen Healthcare, Inc. Quote
Margins
In the quarter under review, NextGen’s adjusted gross profit rose 3.7% to $83.7 million. However, adjusted gross margin contracted 105 basis points (bps) to 55.9%.
Selling, general and administrative expenses fell 3.5% to $47.2 million. Research and development expenses went up 6.6% year over year to $19.4 million. Adjusted operating expenses of $66.6 million dipped 0.8% year over year.
Adjusted operating profit totaled $17.1 million, reflecting a 25.8% uptick from the prior-year quarter. Adjusted operating margin in the fiscal third quarter expanded 183 bps to 11.4%.
Financial Position
NextGen exited the third quarter of fiscal 2022 with cash and cash equivalents of $49.4 million compared with $75.3 million at the end of fiscal second quarter.
Cumulative net cash flow from operating activities at the end of the third quarter of fiscal 2022 was $36.6 million compared with $75.9 million a year ago.
In October 2021, NextGen’s management approved a $60-million share repurchase program. In the reported quarter, the company purchased approximately 2.2 million shares, worth $35.9 million, in the open market.
Fiscal 2022 Guidance
NextGen has raised its financial outlook for fiscal 2022.
The company now projects revenues in the range of $591-$595 million (up from the previously guided range of $584-$590 million). The Zacks Consensus Estimate for the same is pegged at $588.1 million.
Adjusted EPS is now projected in the band of 96 cents-$1.00 (up from the prior guidance of 90-96 cents). The Zacks Consensus Estimate for the same stands at 95 cents.
Our Take
NextGen exited the third quarter of fiscal 2022 with better-than-expected results. Solid uptick in top line, along with strength in both revenue sources of the company, is encouraging. Robust increase in Subscription services revenues in the quarter on the back of solid demand for NGE software-as-a-service and Virtual Visit solutions are encouraging. Expansion in adjusted operating margin bodes well. The provision of an upbeat financial outlook for the year also raises optimism.
On the flip side, year-over-year decline in adjusted EPS is disappointing. Contraction of adjusted gross margin is worrying. NextGen faces intense competition in the MedTech space, raising our apprehensions.
Zacks Rank and Key Picks
NextGen Healthcare currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks that are supposed to report earnings soon are Cerner Corporation , Catalent, Inc. (CTLT - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
The Zacks Consensus Estimate for Cerner’s fourth-quarter 2021 adjusted EPS is currently pegged at 88 cents. The consensus estimate for fourth-quarter 2021 revenues is pegged at $1.49 billion. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cerner has an estimated long-term growth rate of 12.8%. CERN’s earnings yield of 4% compare favorably with the industry’s negative yield.
Catalent currently has a Zacks Rank #2. The Zacks Consensus Estimate for its second-quarter fiscal 2022 adjusted EPS is currently pegged at 84 cents. The consensus estimate for fiscal second-quarter revenues is pinned at $1.16 billion.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings yield of 3.8% compare favorably with the industry’s negative yield.
AMN Healthcare currently flaunts a Zacks Rank #1. The Zacks Consensus Estimate for its fourth-quarter 2021 adjusted EPS is currently pegged at $2.58. The consensus estimate for its revenues stands at $1.28 billion.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings yield of 6.9% compare favorably with the industry’s 1.1%.